GB2410744B - Kinase inhibitors for the treatment of disease - Google Patents

Kinase inhibitors for the treatment of disease

Info

Publication number
GB2410744B
GB2410744B GB0511267A GB0511267A GB2410744B GB 2410744 B GB2410744 B GB 2410744B GB 0511267 A GB0511267 A GB 0511267A GB 0511267 A GB0511267 A GB 0511267A GB 2410744 B GB2410744 B GB 2410744B
Authority
GB
United Kingdom
Prior art keywords
disease
treatment
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0511267A
Other versions
GB2410744A (en
GB0511267D0 (en
Inventor
Steven W Andrews
Michael E Garst
Xialing Guo
Jonathan J Hebert
Thomas Malone
Julie A Wurster
Clarence Eugene Hull Iii
Yuan-Xing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,097 external-priority patent/US6699863B1/en
Priority claimed from US10/389,416 external-priority patent/US6747025B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of GB0511267D0 publication Critical patent/GB0511267D0/en
Publication of GB2410744A publication Critical patent/GB2410744A/en
Application granted granted Critical
Publication of GB2410744B publication Critical patent/GB2410744B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
GB0511267A 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease Expired - Fee Related GB2410744B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30697502A 2002-11-27 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease
PCT/US2003/036988 WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Publications (3)

Publication Number Publication Date
GB0511267D0 GB0511267D0 (en) 2005-07-13
GB2410744A GB2410744A (en) 2005-08-10
GB2410744B true GB2410744B (en) 2006-04-12

Family

ID=32475339

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511267A Expired - Fee Related GB2410744B (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease

Country Status (7)

Country Link
AU (1) AU2003295658A1 (en)
BR (1) BR0316744A (en)
CA (1) CA2507780A1 (en)
DE (1) DE10393799T5 (en)
ES (1) ES2292329B2 (en)
GB (1) GB2410744B (en)
WO (1) WO2004050621A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5053997B2 (en) * 2005-04-28 2012-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds for the treatment of inflammatory diseases
US8367664B2 (en) 2006-01-24 2013-02-05 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CN104211632B (en) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2 indolone derivatives with tyrosine-kinase enzyme inhibition activity and preparation method and application
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Enzyme Inhibition and Medicinal Chemistry Vol. 18, No. 3, 2003, pages 243-252 *

Also Published As

Publication number Publication date
GB2410744A (en) 2005-08-10
WO2004050621A3 (en) 2004-07-15
DE10393799T5 (en) 2005-10-13
AU2003295658A1 (en) 2004-06-23
CA2507780A1 (en) 2004-06-17
ES2292329B2 (en) 2009-09-16
ES2292329A1 (en) 2008-03-01
WO2004050621A2 (en) 2004-06-17
BR0316744A (en) 2005-10-18
GB0511267D0 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
PL373568A1 (en) Use of i kappa b kinase inhibitors for the treatment of pain
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
EP1496910A4 (en) Kinase inhibitors
EP1643986A4 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer s disease
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
SI1569907T1 (en) Nicotinamide-based kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
HUS2200036I1 (en) Use of dihydroimidazolones for the treatment of dogs
HUP0500851A3 (en) Process for the preparation of rosuvastatin
EP1558609A4 (en) Kinase inhibitors
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
GB0320238D0 (en) Treatment of disease
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
EP1569907A4 (en) Nicotinamide-based kinase inhibitors
PL369402A1 (en) Use for the treatment of gastroesophageal reflux disease
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB2410744B (en) Kinase inhibitors for the treatment of disease

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20081119